AAAAAA

   
Results: 1-25 | 26-50 | 51-67 |
Results: 51-67/67
Taxanes in hormone-refractory prostate cancer
Authors: Kang, MH Figg, WD Dahut, W
Citation: Mh. Kang et al., Taxanes in hormone-refractory prostate cancer, CANCER PRAC, 7(5), 1999, pp. 270-272
Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma
Authors: Park, BJ Brown, CK Hu, Y Alexander, HR Horti, J Raje, S Figg, WD Bartlett, DL
Citation: Bj. Park et al., Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma, HUM GENE TH, 10(6), 1999, pp. 889-898
Effects of phenylbutyrate on proliferation and apoptosis in human prostatecancer cells in vitro and in vivo
Authors: Melchior, SW Brown, LG Figg, WD Quinn, JE Santucci, RA Brunner, J Thuroff, JW Lange, PH Vessella, RL
Citation: Sw. Melchior et al., Effects of phenylbutyrate on proliferation and apoptosis in human prostatecancer cells in vitro and in vivo, INT J ONCOL, 14(3), 1999, pp. 501-508
The androgen receptor: genetic considerations in the development and treatment of prostate cancer
Authors: Cude, KJ Dixon, SC Guo, Y Lisella, J Figg, WD
Citation: Kj. Cude et al., The androgen receptor: genetic considerations in the development and treatment of prostate cancer, J MOL MED-J, 77(5), 1999, pp. 419-426
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
Authors: Bubley, GJ Carducci, M Dahut, W Dawson, N Daliani, D Eisenberger, M Figg, WD Freidlin, B Halabi, S Hudes, G Hussain, M Kaplan, R Myers, C Oh, W Petrylak, DP Reed, E Roth, B Sartor, O Scher, H Simons, J Sinibaldi, V Small, EJ Smith, MR Trump, DL Vollmer, R Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells
Authors: Dixon, SC Kruger, EA Bauer, KS Figg, WD
Citation: Sc. Dixon et al., Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells, CANC CHEMOT, 43, 1999, pp. S78-S84
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response
Authors: Kruger, EA Blagosklonny, MV Dixon, SC Figg, WD
Citation: Ea. Kruger et al., UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response, INVAS METAS, 18(4), 1999, pp. 209-218
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis
Authors: Cho, HK Lush, RM Bartlett, DL Alexander, HR Wu, PC Libutti, SK Lee, KB Venzon, DJ Bauer, KS Reed, E Figg, WD
Citation: Hk. Cho et al., Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis, J CLIN PHAR, 39(4), 1999, pp. 394-401
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer
Authors: Senderowicz, AM Reid, R Headlee, D Abornathy, T Horti, J Lush, RM Reed, E Figg, WD Sausville, EA
Citation: Am. Senderowicz et al., A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer, UROL INTERN, 63(2), 1999, pp. 120-125
A facile scheme for phthalimide reversible arrow phthalimidine conversion
Authors: Luzzio, FA Zacherl, DP Figg, WD
Citation: Fa. Luzzio et al., A facile scheme for phthalimide reversible arrow phthalimidine conversion, TETRAHEDR L, 40(11), 1999, pp. 2087-2090
Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma
Authors: Arah, IH Dixon, SC Horti, J Figg, WD
Citation: Ih. Arah et al., Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma, NEOPLASMA, 46(2), 1999, pp. 117-123
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
Authors: Buckner, JC Malkin, MG Reed, E Cascino, TL Reid, JM Ames, MM Tong, WPY Lim, S Figg, WD
Citation: Jc. Buckner et al., Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma, MAYO CLIN P, 74(2), 1999, pp. 137-145
Pharmacokinetics of thalidomide in an elderly prostate cancer population
Authors: Figg, WD Raje, S Bauer, KS Tompkins, A Venzon, D Bergan, R Chen, A Hamilton, M Pluda, J Reed, E
Citation: Wd. Figg et al., Pharmacokinetics of thalidomide in an elderly prostate cancer population, J PHARM SCI, 88(1), 1999, pp. 121-125
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor
Authors: Horti, J Dixon, SC Logothetis, CJ Guo, Y Reed, E Figg, WD
Citation: J. Horti et al., Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor, BR J CANC, 79(9-10), 1999, pp. 1588-1593
Pentosan polysulfate - A polysaccharide that inhibits angiogenesis by binding growth factors
Authors: Figg, WD Pluda, JM Sartor, O
Citation: Wd. Figg et al., Pentosan polysulfate - A polysaccharide that inhibits angiogenesis by binding growth factors, CANC DRUG, 3, 1999, pp. 371-383
Thalidomide - A prodrug that inhibits angiogenesis
Authors: Figg, WD Reed, E Green, S Pluda, JM
Citation: Wd. Figg et al., Thalidomide - A prodrug that inhibits angiogenesis, CANC DRUG, 3, 1999, pp. 407-422
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: Use of a single model for simultaneous determination of changing parameters
Authors: Bauer, KS Kohn, EC Lush, RM Steinberg, SM Davis, P Kohler, D Reed, E Figg, WD
Citation: Ks. Bauer et al., Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: Use of a single model for simultaneous determination of changing parameters, J PHAR BIOP, 26(6), 1998, pp. 673-687
Risultati: 1-25 | 26-50 | 51-67 |